Open AccessEfficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis
Author(s) -
Anthony A. Amato,
Michael G. Hanna,
Pedro Machado,
Umesh A. Badrising,
Hector Chinoy,
Olivier Benveniste,
Ananda Krishna Karanam,
Min Wu,
László B. Tankó,
Agnes Annette Schubert-Tennigkeit,
Dimitris A. Papanicolaou,
Thomas E. Lloyd,
Merrilee Needham,
Christina Liang,
Katrina Reardon,
Marjolein Visser,
Dana P. Ascherman,
Richard J. Barohn,
Mazen M. Dimachkie,
James Miller,
John T. Kissel,
Björn Oskarsson,
Nanette Joyce,
Peter Van den Bergh,
Jonathan Baets,
Jan De Bleecker,
Chafic Karam,
William David,
Massimiliano Mirabella,
Sharon Nations,
Hans H. Jung,
Elena Pegoraro,
Lorenzo Maggi,
Carmelo Rodolico,
Massimiliano Filosto,
Aziz Shaibani,
Kumaraswamy Sivakumar,
Namita Goyal,
Madoka MoriYoshimura,
Satoshi Yamashita,
Naoki Suzuki,
Masashi Akiyama,
Masahisa Katsuno,
Hirokazu Morihata,
Kenya Murata,
Hiroyuki Nodera,
Ichizo Nishino,
Carla Romano,
Valerie Williams,
John Vissing,
Lixin Zhang Auberson
Publication year - 2021
Publication title -
neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.91
H-Index - 364
eISSN - 1526-632X
pISSN - 0028-3878
DOI - 10.1212/wnl.0000000000011626
Subject(s) - placebo , medicine , rash , adverse effect , diarrhea , incidence (geometry) , discontinuation , gastroenterology , physics , alternative medicine , pathology , optics
To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM).